Vantis closed €10M funding round

Vantis, a Munich-based healthcare technology company, has successfully secured €10 million in a new funding round. The investment was led by Angelini Ventures, with significant participation from Bayern Kapital, Twip Impact Ventures, firstminute capital, and b2venture. This capital infusion is intended to advance Vantis's work in early disease detection and expand its market presence.

Vantis focuses on developing innovative at-home diagnostic solutions, with its flagship product being a CE-marked urine test designed for the early detection of chronic kidney disease (CKD). The company plans to utilize the newly acquired funds to expand the reach of its at-